DNA methylation biomarkers for noninvasive detection of triple‐negative breast cancer using liquid biopsy

Abstract

Noninvasive detection of aberrant DNA methylation could provide invaluable biomarkers for earlier detection of triple‐negative breast cancer (TNBC) which could help clinicians with easier and more efficient treatment options. We evaluated genome‐wide DNA methylation data derived from TNBC and normal breast tissues, peripheral blood of TNBC cases and controls and reference samples of sorted blood and mammary cells. Differentially methylated regions (DMRs) between TNBC and normal breast tissues were stringently selected, verified and externally validated. A machine‐learning algorithm was applied to select the top DMRs, which then were evaluated on plasma‐derived circulating cell‐free DNA (cfDNA) samples of TNBC patients and healthy controls. We identified 23 DMRs accounting for the methylation profile of blood cells and reference mammary cells and then selected six top DMRs for cfDNA analysis. We quantified un‐/methylated copies of these DMRs by droplet digital PCR analysis in a plasma test set from TNBC patients and healthy controls and confirmed our findings obtained on tissues. Differential cfDNA methylation was confirmed in an independent validation set of plasma samples. A methylation score combining signatures of the top three DMRs overlapping with the SPAG6, LINC10606 and TBCD/ZNF750 genes had the best capability to discriminate TNBC patients from controls (AUC = 0.78 in the test set and AUC = 0.74 in validation set). Our findings demonstrate the usefulness of cfDNA‐based methylation signatures as noninvasive liquid biopsy markers for the diagnosis of TNBC.

The role of aberrant DNA methylation in cancer initiation and clinical impacts

“…a single gene promoter), 181 – 184 as a panel of loci (e.g. multiple gene promoters) 185 – 189 or using genome-wide epigenetic signatures. 181 , 190 , 191 Some of these approaches have been FDA approved.…”

A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer

“…Indeed, PIK3CA mutation was found in 83% of the metastatic tumor tissue [ 48 ]. Differentially methylated regions at the genome level between normal breast tissue and triple-negative breast cancer tissue demonstrate the utility of methylation signatures as non-invasive liquid biopsy markers for breast cancer diagnosis [ 49 ]. Circulating tumor cells can also be detected in the blood and used as a biomarker for the efficacy or otherwise of treatment of metastatic cancer [ 50 ].…”

Downregulation of JAM3 occurs in cholangiocarcinoma by hypermethylation: A potential molecular marker for diagnosis and prognosis

“…A liquid biopsy provides a non‐invasive or minimally invasive method to extract genetic material from the tumour, with applications extending to early cancer detection, patient follow‐up, assessment of minimal residual disease and potential identification of molecular progression and the mechanism of resistance 8 . Numerous liquid biopsy‐based studies have been conducted in human cancers, including lung, colorectal and breast cancers 9–15 . Wasenang W et al 16 .…”

“… 8 Numerous liquid biopsy‐based studies have been conducted in human cancers, including lung, colorectal and breast cancers. 9 , 10 , 11 , 12 , 13 , 14 , 15 Wasenang W et al. 16 detected methylation of OPCML, HOXA9 and HOXD9 in the serum cell‐free DNA of patients with CCA and other biliary diseases using methylation‐sensitive high‐resolution melting and found significant differences in the methylation levels of OPCML and HOXD9.…”